Godzilla Mounjaro: the nickname explained, and what it tells you about the medicine

Where the "Godzilla" label came from

Picture the landscape of weight-loss medicines before 2022. The best available options were producing average losses of around 5–10% of body weight in trials. Then SURMOUNT-1 published its 72-week results for tirzepatide in the New England Journal of Medicine: participants on the 15mg dose lost an average of roughly 20–21% of starting weight. Some analyses pushed that figure closer to 22.5%. For a clinical trial of a licensed medicine, that was extraordinary, and the internet noticed.

The Godzilla label spread because the numbers felt disproportionate. Forum users and social media posts latched onto it to signal that this was not the same category of result as what had come before. It is informal, obviously, Eli Lilly's name for the medicine is Mounjaro, and the MHRA, NICE, and NHS all refer to tirzepatide. But the nickname stuck because the data gave it somewhere to land. The SURMOUNT programme involved thousands of adults across multiple trials, and the consistency of the findings across doses was unusual enough to generate genuine clinical interest, not just online buzz.

For context on what the medicine actually is and how it works, our tirzepatide overview covers the mechanism in plain language.

What the results look like outside a trial setting

Clinical trial populations are not identical to the general public. SURMOUNT-1 enrolled adults with obesity and no diabetes, all of whom followed a reduced-calorie diet and increased their activity levels alongside the injections. That context matters. The headline 20–21% figure is an average across participants on the highest dose who completed the trial, some lost more, some less, and some discontinued early.

Reaching the 15mg dose takes time. Treatment begins at 2.5mg, a starting level designed to let your body adjust rather than to produce immediate weight loss, and if you are curious about what the second stage of treatment looks like, our page on Mounjaro 2 explains what to expect as you move through the early dose increases. Most people spend four weeks at each level before moving up. That titration exists for a reason: the side effects that discourage some people from continuing (nausea, loose stools, fatigue) tend to be most noticeable after a dose change and usually ease within a week or two. Rushing the schedule does not improve outcomes and increases the likelihood of stopping early.

The Mounjaro treatment page sets out the full licensed dose range and what to expect at each stage.

What the Godzilla comparison misses

The nickname captures the size of the average result. It does not capture what getting there involves. Tirzepatide is a once-weekly subcutaneous injection, you inject into the abdomen, thigh, or upper arm and rotate the site each week. The pen arrives, if you order through a GPhC-registered pharmacy like ours, in plain unbranded packaging via tracked DPD delivery; there is a DPD notification on your phone the morning it is on its way, so you know to be in. It goes straight into the fridge when it arrives, stored between 2 and 8°C.

Alongside the injections, the licence specifies a reduced-calorie diet and increased physical activity. NICE's appraisal of tirzepatide, TA1026, reinforces this: the recommendation is for tirzepatide as part of a managed care pathway, not as a standalone intervention. The wraparound support matters. People who get the most from the medicine are usually those who use the appetite reduction it provides to build sustainable habits (higher protein intake, adequate hydration, strength-preserving exercise) rather than treating the injection as the whole plan.

If you are weighing up costs alongside the clinical picture, our Mounjaro price comparison page explains what UK private treatment typically involves.

Is Mounjaro right for you, and how to find out

The MHRA licenses tirzepatide for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition, things like high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. A lower BMI threshold can apply for some ethnic backgrounds under UK guidance. Carrying a BMI that meets the number is necessary but not sufficient: a prescriber looks at your full medical history, current medicines, and personal circumstances before deciding whether to approve treatment.

Tirzepatide is not suitable during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for anyone under 18. Certain conditions (including a personal or family history of medullary thyroid carcinoma) require particular care, and your prescriber will screen for these. Women taking the oral contraceptive pill should know that tirzepatide can affect how it is absorbed; adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase is the guidance from the NHS, for the same reason.

If you are wondering whether your situation fits the eligibility criteria, this page on Mounjaro eligibility works through the criteria in detail. When you feel ready to take the next step, you can read about la Mounjaro to understand the full scope of what the treatment programme covers, or check your eligibility with our prescribers, the consultation is free, and a real clinician reads your answers the same day.